Additional Study Information: The purpose of this research study is to learn about the effects of the study drug PF 06821497, and to find the best dose for treating small cell lung cancer (SCLC), castration resistant prostate cancer (CRPC), and follicular lymphoma (FL). This study will help researchers learn about the safety of PF-06821497 and how it is absorbed, distributed, broken down, and removed from the body.This research study will be the first time PF-06821497 will be given to people. The dose of PF-06821497 to be used to treat patients is unknown. During Part 1A of this research study, different doses of PF-06821497 were tested in patients with advanced tumors (SCLC CRPC, diffuse large B-cell lymphoma DLBCL, and FL) to determine the starting dose levels for Parts 1B and 2A.